nach oben

Current Rheumatology Reports

Erschienen in:

01.06.2013 | SYSTEMIC LUPUS ERYTHEMATOSUS (M PETRI, SECTION EDITOR)

Top 10 Things to Know About Lupus Activity Measures

verfasst von: Aikaterini Thanou, Joan T. Merrill

Erschienen in: Current Rheumatology Reports | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Accurately measuring lupus disease activity has been a demanding and still unresolved task, considering the complex multisystem nature of the disease and its variability over time and between patients. Various available tools for measurement of lupus disease activity may detect clinical improvement and/or deterioration and can be global or organ-focused. Several measures have demonstrated validity, reliability, and sensitivity to change in observational studies, and some were found useful in randomized controlled trials. Evaluation of their content and metric properties and critical review of their strengths and weaknesses facilitates selection of the appropriate tool according to the outcome of interest, and forms the basis for their optimization. In this review, we highlight recent progress in lupus disease activity measures and point to future directions in this field, with a focus on novel composite measurements derived by combining outcome measures in ways that might compensate for their individual deficiencies.

Griffiths B, Mosca M, Gordon C. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol. 2005;19:685–708.PubMedCrossRef

Romero-Diaz J, Isenberg D, Ramsey-Goldman R. Measures of adult systemic lupus erythematosus: updated version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2 K), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Arthritis care & research. 2011;63 Suppl 11:S37–46.CrossRef

Albrecht J, Taylor L, Berlin JA, et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol. 2005;125:889–94.PubMed

Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009;61:1143–51.PubMedCrossRef

• Wallace D, Strand V, Furie R, et al. Evaluation of Treatment Success in Systemic Lupus Erythematosus Clinical Trials: Development of the British Isles Lupus Assessment Group-Based Composite Lupus Assessment Endpoint. Arthritis Rheum. 2011;63:S894. The first description of the BILAG-Based Composite Lupus Assessment.CrossRef

The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. Arthritis Rheum. 2004;50:3418-3426.

Gordon C, Bertsias G, Ioannidis JP, et al. EULAR points to consider for conducting clinical trials in systemic lupus erythematosus. Ann Rheum Dis. 2009;68:470–6.PubMedCrossRef

Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992;35:630–40.PubMedCrossRef

Buyon JP, Petri MA, Kim MY, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med. 2005;142:953–62.PubMed

10.

Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005;353:2550–8.PubMedCrossRef

11.

Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29:288–91.PubMed

12.

Touma Z, Urowitz MB, Ibanez D, Gladman DD. SLEDAI-2 K 10 days versus SLEDAI-2 K 30 days in a longitudinal evaluation. Lupus. 2011;20:67–70.PubMedCrossRef

13.

Gladman DD, Urowitz MB, Kagal A, Hallett D. Accurately describing changes in disease activity in Systemic Lupus Erythematosus. J Rheumatol. 2000;27:377–9.PubMed

14.

• Yee CS, Farewell VT, Isenberg DA, et al. The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology (Oxford). 2011;50:982–8. Analysis of data from 2 large multi-center studies to determine SLEDAI-2 K sensitivity to change in disease activity over time using change in therapy as the reference standard.CrossRef

15.

Ward MM, Marx AS, Barry NN. Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. J Rheumatol. 2000;27:664–70.PubMed

16.

• Touma Z, Gladman DD, Ibanez D, Urowitz MB. Development and initial validation of the systemic lupus erythematosus disease activity index 2000 responder index 50. J Rheumatol. 2011;38:275–84. First detailed description of the SRI-50 definitions and scoring.PubMedCrossRef

17.

Touma Z, Urowitz MB, Fortin PR, et al. Systemic lupus erythematosus disease activity index 2000 responder index-50: a reliable index for measuring improvement in disease activity. J Rheumatol. 2011;38:868–73.PubMedCrossRef

18.

Touma Z, Gladman DD, Ibanez D, et al. Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 enhances the ability of SLE Responder Index to identify responders in clinical trials. J Rheumatol. 2011;38:2395–9.PubMedCrossRef

19.

Touma Z, Urowitz MB, Taghavi-Zadeh S, et al. Systemic lupus erythematosus disease activity Index 2000 Responder Index 50: sensitivity to response at 6 and 12 months. Rheumatology (Oxford). 2012;51:1814–9.CrossRef

20.

Touma Z, Gladman DD, Ibanez D, Urowitz MB. SLEDAI-2 K Responder Index 50 captures 50 % improvement in disease activity over 10 years. Lupus. 2012;21:1305–11.PubMedCrossRef

21.

Hay EM, Bacon PA, Gordon C, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med. 1993;86:447–58.PubMed

22.

Stoll T, Stucki G, Malik J, et al. Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus. Ann Rheum Dis. 1996;55:756–60.PubMedCrossRef

23.

Isenberg DA, Rahman A, Allen E, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford). 2005;44:902–6.CrossRef

24.

Yee CS, Farewell V, Isenberg DA, et al. Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity. Arthritis Rheum. 2006;54:3300–5.PubMedCrossRef

25.

Yee CS, Farewell V, Isenberg DA, et al. British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum. 2007;56:4113–9.PubMedCrossRef

26.

Yee CS, Farewell V, Isenberg DA, et al. The BILAG-2004 index is sensitive to change for assessment of SLE disease activity. Rheumatology (Oxford). 2009;48:691–5.CrossRef

27.

Cresswell L, Yee CS, Farewell V, et al. Numerical scoring for the Classic BILAG index. Rheumatology (Oxford). 2009;48:1548–52.CrossRef

28.

Yee CS, Cresswell L, Farewell V, et al. Numerical scoring for the BILAG-2004 index. Rheumatology (Oxford). 2010;49:1665–9.CrossRef

29.

• Yee CS, Gordon C, Isenberg DA, et al. The BILAG-2004 systems tally--a novel way of representing the BILAG-2004 index scores longitudinally. Rheumatology (Oxford). 2012;51:2099–105. A novel alternative approach to longitudinally represent the BILAG-2004 system scores that is both clinically meaningful and easier to analyze compared to multiple catergorical variables.CrossRef

30.

Bonilla-Martinez ZL, Albrecht J, Troxel AB, et al. The cutaneous lupus erythematosus disease area and severity index: a responsive instrument to measure activity and damage in patients with cutaneous lupus erythematosus. Arch Dermatol. 2008;144:173–80.PubMedCrossRef

31.

• Klein R, Moghadam-Kia S, LoMonico J, et al. Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. Arch Dermatol. 2011;147:203–8. Analysis evaluating the use of CLASI in classifying patients according to disease severity and in identifying responders to therapy.PubMedCrossRef

32.

Jolly M, Kazmi N, Mikolaitis RA, et al. Validation of the Cutaneous Lupus Disease Area and Severity Index (CLASI) using physician- and patient-assessed health outcome measures. J Am Acad Dermatol. 2012.

33.

The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum. 2006;54:421-432.

34.

Petri M, Kasitanon N, Lee SS, et al. Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index. Arthritis Rheum. 2008;58:1784–8.PubMedCrossRef

35.

Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20:1103–12.PubMedCrossRef

36.

Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64:1215–26.PubMedCrossRef

37.

•• Wofsy D, Hillson JL, Diamond B. Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum. 2012;64:3660–5. Insightful post hoc analysis of the abatacept lupus nephritis trial dataset by use of previously proposed response criteria that provides an evidence-based rational for choosing among alternative definitions of response.PubMedCrossRef

38.

Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis and rheumatism. 2011;63:3918–30.PubMedCrossRef

39.

Wallace DJ, Kalunian K, Petri MA, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis. 2013. doi:10.1136/annrheumdis-2012-202760. [Epub ahead of print].

40.

•• Petri M, Pike MC, Kelley L, et al. Systemic Lupus Erythematosus Responder Index Assessment of Responders in EMBLEM, a Phase IIb Study in Patients with Moderate to Severe Systemic Lupus Erythematosus. Arthritis Rheum. 2011;63:S548. Post hoc analysis of the dataset from the phase II EMBLEM study by use of the SRI in comparison to BICLA.

41.

• Sridharan ST, Zhou T, Immermann F, et al. Low Placebo Responses and Clinical Components of the Biomarkers of Lupus Disease (BOLD) Study May Provide Useful Insights for Systemic Lupus Erythematosus Clinical Trial Design. Arthritis Rheum. 2011;63:S552. Comparion of the SRI and BICLA to the simpler BOLD improvement criteria anchored to the clinician's impression of response.

42.

• Ruperto N, Hanrahan LM, Alarcon GS, et al. International consensus for a definition of disease flare in lupus. Lupus. 2011;20:453–62. Consensus definition of disease flare in lupus derived by a international working group of physicians after a formal DEPHI exercise.PubMedCrossRef

43.

•• Isenberg DA, Allen E, Farewell V, et al. An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA. Ann Rheum Dis. 2011;70:54–9. Comparison of flares defined by the BILAG-2004 flare index and the SELENA flare index in a real world exercise that also incorporated the physician's global assessment and a panel assessment of flares.PubMedCrossRef

44.

Kalunian K, Merrill JT, Maciuca R, et al. Efficacy and Safety of Rontalizumab (Anti-Interferon Alpha) in SLE Subjects with Restricted Immunosuppressant Use: Results of A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study. Arthritis Rheum. 2012;64:S1123.CrossRef

45.

Gordon C, Sutcliffe N, Skan J, et al. Definition and treatment of lupus flares measured by the BILAG index. Rheumatology (Oxford). 2003;42:1372–9.CrossRef

Titel: Top 10 Things to Know About Lupus Activity Measures
verfasst von: Aikaterini Thanou
Joan T. Merrill
Publikationsdatum: 01.06.2013
Verlag: Current Science Inc.
Erschienen in: Current Rheumatology Reports / Ausgabe 6/2013
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-013-0334-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2013

Vaccination and Inflammatory Arthritis: Overview of Current Vaccines and Recommended Uses in Rheumatology

Use of New Oral Anticoagulants in Antiphospholipid Syndrome

Understanding Developmental Mechanisms in the Context of Osteoarthritis

Autoantibodies in Polymyositis and Dermatomyositis

Clinical Management of Septic Arthritis